However, although HNSCC is considered as one of the tumors with the highest frequency of PD-L1 positivity (57–82% of cases), less than 20% of HNSCC patients show an objective response to ICI treatment within the FDA settings, while most patients exhibit primary resistance [169]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.